Stephens Inc. AR Increases Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Stephens Inc. AR increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 16.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 717 shares of the company’s stock after purchasing an additional 101 shares during the quarter. Stephens Inc. AR’s holdings in Medpace were worth $239,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in MEDP. J.Safra Asset Management Corp increased its holdings in Medpace by 87.0% during the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock valued at $41,000 after acquiring an additional 47 shares in the last quarter. DT Investment Partners LLC acquired a new stake in shares of Medpace during the 2nd quarter worth about $41,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Medpace during the 2nd quarter worth about $52,000. EntryPoint Capital LLC acquired a new stake in shares of Medpace during the 1st quarter worth about $54,000. Finally, International Assets Investment Management LLC acquired a new stake in shares of Medpace during the 2nd quarter worth about $61,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of MEDP opened at $362.79 on Friday. Medpace Holdings, Inc. has a 1 year low of $268.80 and a 1 year high of $459.77. The company has a market cap of $11.28 billion, a price-to-earnings ratio of 31.77, a price-to-earnings-growth ratio of 1.98 and a beta of 1.37. The firm has a fifty day moving average of $341.59 and a 200-day moving average of $377.50.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The business had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. During the same quarter in the prior year, the company posted $2.22 earnings per share. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. Analysts predict that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and decreased their price target for the stock from $415.00 to $345.00 in a research note on Wednesday, September 25th. Guggenheim decreased their price target on shares of Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a research note on Wednesday, July 24th. William Blair reissued an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research report on Wednesday, July 24th. Finally, Redburn Atlantic assumed coverage on shares of Medpace in a research report on Monday, October 14th. They issued a “buy” rating and a $404.00 target price on the stock. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Medpace presently has a consensus rating of “Hold” and a consensus price target of $380.00.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.